EGFR and non-small cell lung carcinoma: The current real-world study shed insight into the effectiveness and safety of anlotinib as an add-on therapy to ongoing systemic therapy in the context of primary treatment in EGFR mutant NSCLC patients who developed gradual or oligo-progression while on first-line third-generation EGFR TKI therapy.